Bond Eli Lilly & Company 5% ( US532457CE69 ) in USD
| Issuer | Eli Lilly & Company |
| Market price | |
| Country | United States
|
| ISIN code |
US532457CE69 ( in USD )
|
| Interest rate | 5% per year ( payment 2 times a year) |
| Maturity | 27/02/2026 |
|
Prospectus brochure in PDF format is unavailable at this time We will provide it as soon as possible |
|
| Minimal amount | 2 000 USD |
| Total amount | 750 000 000 USD |
| Cusip | 532457CE6 |
| Standard & Poor's ( S&P ) rating | A+ ( Upper medium grade - Investment-grade ) |
| Moody's rating | Aa3 ( High grade - Investment-grade ) |
| Next Coupon | 27/02/2026 ( In 75 days ) |
| Detailed description |
Eli Lilly and Company is a global pharmaceutical company specializing in the research, development, manufacturing, and marketing of pharmaceutical products and biologicals. This financial analysis details a specific bond issued by Eli Lilly, a prominent pharmaceutical company headquartered in the United States, identified by its ISIN US532457CE69 and CUSIP 532457CE6. The bond, denominated in USD, carries an annual interest rate of 5% and features a total issue size of $750,000,000, with a maturity date of February 27, 2026. Interest payments are made semiannually, and the bond is currently trading at 99.956% of its par value on the market, with a minimum purchase amount set at $2,000. This debt instrument benefits from robust credit ratings, having received an A+ from Standard & Poor's and an Aa3 from Moody's, reflecting Eli Lilly's strong financial standing. |
Français
Italiano
United States